Covered recipient · General Payments record
RANDY S LONGMAN
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$126,867.73
- Reported across 55 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $14,755.00 | 2 |
| Food and Beverage | $585.38 | 11 |
| Travel and Lodging | $556.14 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $9,750.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $5,591.01 | 3 |
| Celgene Corporation | $223.70 | 5 |
| Janssen Biotech, Inc. | $184.91 | 2 |
| ABBVIE INC. | $131.82 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.08 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.66 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899389 | CMS |
| ABBVIE INC. | $105.16 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899391 | CMS |
| Celgene Corporation | $118.00 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101184971 | CMS |
| Celgene Corporation | $18.91 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101184985 | CMS |
| Celgene Corporation | $4.95 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101184987 | CMS |
| Celgene Corporation | $56.89 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101184989 | CMS |
| Celgene Corporation | $24.95 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101184979 | CMS |
| E.R. Squibb & Sons, L.L.C. | $29.87 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101775286 | CMS |
| E.R. Squibb & Sons, L.L.C. | $556.14 | 03/18/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1101775022 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5,005.00 | 04/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101775030 | CMS |
| Janssen Biotech, Inc. | $59.91 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078456122 | CMS |
| Janssen Biotech, Inc. | $125.00 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078442859 | CMS |
| PFIZER INC. | $9,750.00 | 09/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131906526 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.08 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137623192 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.